Indication
For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Loading your page…
Loading your page…
Amyloid Neuropathies, Familial
Marketing Authorisation Holder: Bayer AG
EMA Authorisation: 10/02/2025
INN: acoramidis
AI Drug & Interaction Analysis
Free account required
Ask Osler about Beyonttra: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.